Study of XL114 in Subjects With Non-Hodgkin's Lymphoma
Status:
Not yet recruiting
Trial end date:
2025-12-11
Target enrollment:
Participant gender:
Summary
This is a Phase 1, non-randomized, open-label, dose-escalation and expansion study,
evaluating the safety, tolerability, PK, pharmacodynamics, and preliminary clinical antitumor
activity of XL114 administered alone orally to subjects with Non-Hodgkin's Lymphoma (NHL).
The objectives of the study also include determining the recommended dose (RD) and/or maximum
tolerated dose (MTD) of XL114.